Insights: AlertsUSPTO Issues Guidance on Options to Amend through Reissue and Reexamination during AIA TrialsApril 22, 2019 On October 29, 2018, the US Patent & Trademark Office (USPTO or Office) issued a Notice requesting comments on proposed modifications to motion to amend (MTA) practice. The Office received a number of comments and questions concerning the interplay between reexamination and reissue proceedings during a co-pending AIA trial (inter partes review (IPR), post grant review (PGR) or covered business method (CBM) review). Today, the USPTO responded to those comments by publishing a Notice discussing the handling of requests to amend claims through reexamination and reissue proceedings during co-pending AIA trials. Notably, the Notice was intended to summarize rather than amend or alter existing practice. The Office indicated that it will consider a reissue application or a request for reexamination any time before, but not after, either (1) the Office issues a trial certificate cancelling all claims in a patent, or (2) the Federal Circuit issues a mandate concerning a decision finding all claims invalid. The Office will issue trial certificates after either the period for filing a notice of appeal from an AIA trial decision has closed (63 days after (i) a final written decision (FWD) or (ii) a decision on a request for rehearing following a FWD)), or an appeal to the Federal Circuit has been finally resolved. Additional important takeaways from the Notice include:
Today's USPTO Notice continues Director Iancu's push to provide meaningful mechanisms for permitting PO's to amend claims during AIA trials. Now, in addition to the recently-launched MTA pilot program, which provides PO's up to two opportunities to present amended claims, the Office has confirmed that PO's may file for reissue or reexamination, even after a negative FWD, effectively affording a third opportunity for PO's to amend their claims. Related PeopleJustin L. KriegerPartner Denver, CO jkrieger@kilpatricktownsend.com |